Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.52 |
| ▸ | TNK2 | Q07912 | 9/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL169600 | 0.90 | BTK (0.53) | BTKTNK2PIK3CDPIK3CAPIK3CG | |
| SCHEMBL169601 | 0.90 | BTK (0.53) | BTKTNK2PIK3CDPIK3CAPIK3CG | |
| SCHEMBL170027 | 0.86 | BTK (0.61) | BTKTNK2PIK3CDPIK3CAPIK3CG | |
| SCHEMBL169823 | 0.83 | BTK (0.61) | BTKTNK2 | |
| SCHEMBL122913 | 0.82 | BTK (0.60) | BTKTNK2 | |
| SCHEMBL124219 | 0.82 | BTK (0.49) | BTKTNK2PIK3CD | |
| SCHEMBL12100517 | 0.81 | BTK (0.61) | BTKTNK2 | |
| SCHEMBL122924 | 0.81 | BTK (0.61) | BTKTNK2PIK3CDPIK3CAPIK3CG | |
| SCHEMBL122300 | 0.78 | BTK (0.61) | BTKTNK2 | |
| SCHEMBL123116 | 0.77 | BTK (0.58) | BTKTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765754-B2 | Pyrrolotriazine compounds | LOCUS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2424368-A1 | PYRROLOTRIAZINE COMPOUNDS | Locus Pharmaceuticals, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126960-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | BTK, SYK, ZAP70 | BTK 1/4885TNK2 511/4885PIK3CD 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.